The following tables present disaggregated expenses that are regularly provided to the CODM:


	Year Ended December 31,
	2025	2024	2023
Personnel compensation and related costs	87,894	106,154	115,749
Licensing fees	30,597	30,997	19,291
CROs/CMOs/Investigators expenses	73,763	69,870	103,333
Other costs	28,650	27,483	27,495
Total research and development expenses	220,904	234,504	265,868


	Year Ended December 31,
	2025	2024	2023
Clinical programs	86,934	86,126	112,158
Pre-Clinical programs	24,293	31,913	17,356
Unallocated research and development expenses	109,677	116,465	136,354
Total research and development expenses	220,904	234,504	265,868


	Year Ended December 31,
	2025	2024	2023
Personnel compensation and related costs	165,005	174,958	173,389
Other costs	112,600	123,783	108,219
Total selling, general, and administrative expenses	277,605	298,741	281,608


	Twelve months ended December 31
	2025	2024	2023
Selling and marketing expenses	187,562	190,367	169,555
General and administrative expenses	90,043	108,374	112,053
Total selling, general, and administrative expenses	277,605	298,741	281,608